TORONTO and SAN DIEGO (September 25, 2015) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that it has received approval from Health Canada to initiate its Phase 1 clinical study of marizomib in combination with bevacizumab (Avastin®) in patients with recurrent malignant glioma in Canada. Marizomib is a novel and highly potent proteasome inhibitor that readily penetrates the blood brain barrier. It prevents the breakdown of proteins involved in signal ...
Co-development agreement, brokered by MaRS Innovation, to advance ultrasound chemotherapy monitoring technology as clinical tool
TORONTO (March 12, 2015) — Sunnybrook Health Sciences Centre and MaRS Innovation today announced a co-development agreement for WaveCheck, an ultrasound technology that transforms conventional equipment so that physicians can monitor a breast cancer tumour’s response to chemotherapy.
This announcement was covered in Biotechnology Focus, Aunt Minnie.com (radiology blog), dotmed.com, Bio-Medicine.org, Bloomberg Business and Research Views.
The partnership with GE Healthcare, brokered by MaRS Innovation, seeks to develop WaveCheck ...
Toronto-based AvidBiologics Inc., a leading Canadian biotech company, and the National Research Council of Canada (NRC) are collaborating on one of the most promising advances in the fight against cancer: antibody-drug conjugates (ADCs).
Recently signed research and licensing agreements will enable both organizations to continue developing a series of ADCs targeting breast, lung, and head-and-neck cancers. Unlike chemotherapy, ADCs specifically seek and destroy cancer cells, with minimal impact on healthy cells.
"The work performed by NRC is crucial to assembling the data package ...
The Council of Academic Hospitals of Ontario's online magazine highlighted WaveCheck on February 3, 2014 as a more personalized approach to cancer treatments because of the technology's ability to effectively monitor chemotherapy response.
WaveCheck's technology, invented by Dr. Gregory Czarnota of Sunnybrook Health Sciences Centre and Professor Michael C. Kolios of Ryerson University, allows women and men undergoing chemotherapy for breast cancer to know if their treatment is working at the beginning of treatment (within one to four weeks) rather than at ...